Remove clinical adhd
article thumbnail

Cingulate partners with Indegene for ADHD therapy

Pharmaceutical Technology

Biopharmaceutical firm Cingulate and life sciences commercialisation firm Indegene have entered into a joint commercialisation deal for the former’s attention-deficit/hyperactivity disorder (ADHD) therapy CTx-1301 (dexmethylphenidate).

article thumbnail

Akili digital therapeutic shows promise in lupus patients

pharmaphorum

Akili looks like it could bring another digital therapeutic (DTx) to market after a clinical trial backed the efficacy of its AKL-T01 in patients with the autoimmune disorder systemic lupus erythematosus (SLE). EndeavorRx screen shot.

Patients 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Jeff Casberg, MS, RPh, Senior Vice President of Clinical Pharmacy at IPD Analytics, a managed care and pharmaceutical consultancy, highlighted a wide range of 2023 key events that will affect managed care professionals by the end of the year. The six entrants launched in August could help resolve some of the shortages in ADHD.”

article thumbnail

The Issues That Matter Most in 2023: Medical Metaverse

Eversana Intouch

It’s especially important in categories adopting metaverse efforts early, such as mental health (PTSD, anxiety, depression), neurology (ADHD, MS, pain management), and procedure-driven specialties like surgery. Evaluate potential synergies and partnerships with digital therapeutics.

Medical 52
article thumbnail

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

Clinical trials of gameChangerVR have been run with both the National Health Service (NHS) and the US veteran’s charity Wounded Warrior Project. XRHealth launched a VR therapy application in 2020 designed to treat attention deficit hyperactivity disorder (ADHD).

article thumbnail

Mental health apps and services may be doing more harm than good

World of DTC Marketing

Cerebral will stop writing prescriptions for Adderall, Ritalin, and other controlled substances to new ADHD patients as concerns grow about telehealth companies’ prescribing practices. Many mHealth apps also collect sensitive mental-health data to sell for ad revenue. The most significant potential risk of this is the unknown.

Patients 252
article thumbnail

CMO Moves: Regulatory catalysts for drug manufacturing-April

Pharmaceutical Technology

Janssen Pharmaceutical Companies of Johnson and Johnson’s one-shot vaccine will now be indicated when other vaccines are not accessible or when it is clinically appropriate for adults. . The FDA also expanded the label for Supernus Pharmaceuticals’ drug Qelbree to also include attention deficit hyperactivity disorder (ADHD).